Safety and Acceptance of COVID-19 Vaccination After Multisystem Inflammatory Syndrome in Children (MIS-C) in Spain

J Pediatric Infect Dis Soc. 2022 Oct 25;11(10):471-473. doi: 10.1093/jpids/piac076.

Abstract

In this cohort of 42 adolescents with a previous multisystem inflammatory syndrome (MIS-C) diagnosis, 32 (76.2%) were vaccinated with COVID-19 vaccines, with a low incidence of relevant adverse events. More importantly, no new MIS-C or myocarditis occurred after a median of 10 weeks (range 5.3-19.7) post-vaccination.

Keywords: COVID-19; acceptance; multisystem inflammatory syndrome in children (MIS-C); safety; vaccination.

MeSH terms

  • Adolescent
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Child
  • Humans
  • Spain / epidemiology
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related